Johnson & Johnson Agrees to Pay $5.5 Billion to Resolve Talcum Powder Cancer Litigation

Johnson & Johnson (J&J) announced on July 27, 2026 that it had reached a proposed settlement to resolve approximately 76,000 talcum powder ovarian cancer lawsuits that had accumulated in federal and state courts over more than a decade of litigation. The company committed $5.5 billion toward the resolution, with its first payment not to exceed $3 billion due in 2027 and no additional payments required before 2028. The proposed settlement is conditioned on the participation of at least 95 percent of the remaining claimants before it is finalized. J&J had previously resolved approximately 95 percent of its mesothelioma lawsuits, all state consumer protection claims, and all disputes with talc suppliers, leaving ovarian cancer claims as the last major category of outstanding talc litigation.¹

A Show Cause Order Preceded the Settlement

Five days before the settlement announcement, U.S. Magistrate Judge Rukhsanah Singh ordered plaintiffs in the consolidated federal talc litigation pending in the District of New Jersey to show cause why their remaining claims should not be dismissed. The order followed the withdrawal of plaintiffs’ specific causation experts, Dr. Judith Wolf and Dr. Daniel Clarke-Pearson, in preparation for two bellwether trials, after a hearing found that their opinions were not grounded in reliable scientific methodologies. A bellwether trial is a test case selected from a larger pool of consolidated claims to be tried first, with the results used to gauge how juries evaluate the merits of the broader litigation and to inform settlement negotiations among all parties.²

The court’s concern centered on the plaintiffs’ inability to demonstrate that J&J’s talcum powder specifically caused each individual plaintiff’s ovarian cancer, a legal standard known as specific causation.³

J&J Characterizes the Settlement as a Vindication

Erik Haas, Worldwide Vice President of Litigation for J&J, framed the settlement as the conclusion of litigation he maintained was without merit from the start:

The Court’s order placed plaintiffs in an untenable position of having to present specific causation evidence to maintain their claims that does not exist. While we are confident the Company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the Company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives.⁴

Plaintiff Attorneys Saw It Differently

Plaintiff’s counsel, Christopher Seeger told another side of the story about the decade-long litigation had cost the women and families involved.

Seeger explained:

More than a decade of protracted litigation and three failed bankruptcies has left tens of thousands of women and their families waiting far too long for relief. Tragically, many did not live to see this day”

Unlike a fixed settlement pool that divides a set amount among all claimants, J&J’s total payment obligation here has no ceiling. The minimum amount that J&J must pay is $5.8 billion, and that number grows with the number of qualifying claims. Attorneys leading the litigation were clear that this resolution came only after more than a decade of fighting and three failed attempts by J&J to use the bankruptcy system to end the cases entirely.⁵

Three Attempts at Bankruptcy

Rather than litigate the claims in court, J&J turned to the federal bankruptcy system three times in an effort to limit its payout for any liability with its baby powder. J&J’s first two attempts were carried out through a subsidiary called LTL Management LLC, and both were rejected by the Third Circuit Court of Appeals. The company then formed a new subsidiary, Red River Talc LLC, and filed for bankruptcy protection a third time in September 2024. A bankruptcy court dismissed that case in March 2025. J&J announced it would not appeal, returning all pending claims to the federal and state courts.⁶

By the time the settlement was announced, more than 67,000 cases remained pending in the consolidated federal litigation alone, with thousands more proceeding simultaneously in state courts across the country.⁷

What Johnson & Johnson Knew

Plaintiff attorneys who spent more than a decade building the talc litigation argued that J&J had knowledge of the problem long before it acted on it. The drug giant spent more than sixty years promoting Johnson’s Baby Powder as one of the most trusted consumer products in American households, marketing it for use on women’s bodies and on their babies. Research dating to the 1970s identified talc particles in the ovarian tissue of women who had regularly used the powder. By the 1980s, population-level studies had begun connecting regular use of the powder to ovarian cancer diagnoses.⁸

According to the plaintiff attorneys, internal J&J documents showed that the company was not only aware of the risk, but also refused to change to a safer formula and made the decision to keep selling a product they knew posed serious health risks without warning the public.

Safety concerns about the talc product surfaced as far back as the 1950s, long before any litigation began. The first lawsuit directly alleging that the product caused cancer was filed in 2009, more than half a century later. Internal documents produced through discovery during the litigation allegedly showed that J&J had been aware since the early 1970s that some samples of its talc supply contained asbestos, a known carcinogen linked to both ovarian cancer and mesothelioma.

Despite the company’s awareness of the dangers its product could cause, it failed to issue a consumer warning, refused product reformulation, and did not pursue regulatory disclosure at the time. During this same period, internal company records showed that J&J was simultaneously pursuing a marketing strategy aimed at what those documents describe as “under-developed geographical areas,” with Black women identified as the primary consumer demographic. Distribution networks ran through community organizations, churches, and beauty salons in those areas. Radio advertising designed to reach “curvy Southern women aged 18-49 skewing African-American” was deployed across six distinct U.S. markets through the 1990s and into the early 2000s.⁹

J&J finally reformulated its baby powder in the United States and Canada in 2020, replacing talc with cornstarch, and discontinued its talc-based product globally in 2023. These product changes arrived only after the litigation was already well underway and had produced years of damaging verdicts.

A Record of Large Verdicts

Before the settlement, juries had returned significant verdicts against J&J in talc cases across the country. In 2019, a Missouri jury awarded $2.12 billion to twenty-two women who alleged that J&J’s baby powder caused their ovarian cancer. In October 2025, a Los Angeles jury found J&J liable for $966 million in the case of Mae Moore, who died at the age of 88 from mesothelioma after decades of using the company’s powder. A judge overturned $950 million in punitive damages from that award in March 2026, allowing $16 million in compensatory damages to stand. J&J has reported spending more than $3 billion defending talc claims over the course of the litigation.¹⁰

Even as it announced the settlement, J&J maintained that its talcum powder products never contained asbestos and that decades of independent scientific research do not support any link between cosmetic talc and cancer.¹¹

If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.